arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Cyclerion Therapeutics, Inc.

CYCN

$3.60 0.00 (0.00%) at close

9 Visible periods

28 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Cyclerion Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $11.5M

Dividend Yield —

Revenue Growth 3.7%

Op. Margin -239.8% ↘

ROIC -54.7% ↘

FCF / Share $-1.04 ↗

Trailing P/E —

Price / Book 1.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 6, 2026.

9-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$2.07M

↑ +3.7% —

Net Income Profit after all expenses

$-3.53M

↓ -15.4% —

Operating Margin Operating profit as % of sales

-239.8%

↓ -32.2% 0th

FCF / Share Free cash flow per share

$-1.04

↑ +39.5% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓

Returns ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Revenue Growth YoY (%)	3.7% Caution Caution Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-54%)	—	N/M	-58.8% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-835%)	71.7% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+796%)	-49.1% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-713%)	—	—	—
EPS Growth YoY (%)	8.3% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	46.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-122.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	23.5% Good Good Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	-15.4% Weak Weak Year-over-year change in net income	41.9% Excellent Excellent Year-over-year change in net income	N/M	N/M	33.6% Excellent ↑ Excellent Improving Year-over-year change in net income	36.8% Excellent Excellent Year-over-year change in net income	-6.7% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	39.5% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	81.1% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-872.6% Weak Weak Year-over-year change in free cash flow	-0.1% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—
Revenue CAGR 3Y (%)	8.5% Fair ↑ Fair Improving Compound annual revenue growth over 3 years	-20.2% Weak Weak Compound annual revenue growth over 3 years	—	-28.8% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—	—
Revenue CAGR 5Y (%)	-2.0% Weak Weak Compound annual revenue growth over 5 years	-15.0% Weak Weak Compound annual revenue growth over 5 years	—	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Operating Margin (%) (%)	-239.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1699%)	-181.4% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1309%)	—	—	—	—	—	—	—
Effective Tax Rate (%) (%)	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	-170.1% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1518%)	-152.8% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1374%)	—	—	—	—	—	—	—
FCF Margin (%) (%)	-159.8% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-216.7% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—	—
FCF / Net Income (x)	0.94x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.42x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	4.04x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	-0.92x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.71x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Return on Invested Capital (%)	-54.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-41.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-114.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-424.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-114.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-107.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-127.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	1103.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-49.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-37.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-96.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-245.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-93.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-70.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-67.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-1557.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-38.8% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-359%)	-34.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-330%)	-46.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-411%)	—	-107.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-814%)	-130.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-972%)	-125.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-939%)	—	—

⚖️ Is the balance sheet risky? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Debt to Equity (x)	—	—	—	0.33x Good Good Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-44%)	—	0.06x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-90%)	—	—	—
Net Debt (USD)	$-3.24M	$-3.23M	$-7.57M	$-9.88M	$-53.96M	$-50.90M	$-94.89M	—	—
Debt / EBITDA (x)	—	—	—	-0.08x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	-0.04x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Revenue per Share (USD)	$0.65	$0.79	$0.00	$0.04	$0.10	—	—	—	—
Basic EPS, GAAP (USD)	$-1.11	$-1.21	$-2.25	$-1.01	$-1.32	—	—	—	—
Free Cash Flow per Share (USD)	$-1.04	$-1.72	$-9.09	$-0.93	$-0.93	—	—	—	—
Book Value per Share (USD)	$2.38	$3.48	$4.56	$0.24	$1.11	$1.75	$3.54	—	—
Tangible Book Value per Share (USD)	$2.38	$3.48	$4.56	$0.24	$1.11	$1.75	$3.54	—	—
Basic Weighted Avg Shares (shares)	3.18M	2.52M	2.34M	43.47M	39.14M	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Working Capital (USD)	$3.73M	$3.50M	$5.94M	$7.19M	$44.37M	$41.55M	$82.95M	$-16.97M	—
Total Equity (USD)	$9.09M	$8.85M	$11.29M	$10.45M	$48.25M	$59.49M	$97.73M	$-10.45M	$-8.57M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Sales/Revenue/Turnover (USD)	$2.07M	$2.00M	$0.00	$1.62M	$3.94M	$2.30M	$4.51M	—	—
Net Income, GAAP (USD)	$-3.53M	$-3.06M	$-5.26M	$44.10M	$-51.65M	$-77.80M	$-123.01M	$-115.25M	—
Operating Cash Flow (USD)	$-3.31M	$-4.33M	$-21.25M	$-40.61M	$-36.52M	$-72.49M	$-102.22M	$-97.50M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 34 quarters

Cyclerion Therapeutics, Inc.

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CYCN with peers